
    
      This study is a randomized, double-blind, placebo-controlled study to evaluate the safety,
      pharmacokinetics and efficacy of a single dose of STI-1499 (COVI-GUARDâ„¢), a COVID-19
      targeting monoclonal antibody, in hospitalized patients with moderate COVID-19. Four dose
      levels will be tested: 10 mg, 30 mg, 100 mg, and 200 mg.
    
  